Combination of nivolumab (anti-programmed cell death protein 1 (PD-1) antibody) plus ipilimumab (anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody) was approved for HCC patients previously treated with sorafenib, based on the CheckMate 040 trial [12]. Here, PDCD1 is linked to hepatocellular carcinoma.